Vaccines and methods for using the same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 13, 2015
Grant Date -
Jun 18, 2015
app pub date -
Nov 24, 2014
filing date -
Oct 29, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully